Additional univariate and multivariate analyses confirmed the prognostic power of the SFI-induced MYC signature in predicting prostate cancer progression to a metastatic disease, even after adjusting for gleason grade or the Cell Cycle Progression score consisting of 31 cell cycle genes (Supplementary Tables 3–5)37. This evidence concerns the gene MYC and prostate carcinoma.